Cann GroupASX:CAN +12.50% Debt-to-EBITDA is 0.22 as of Dec. 2025. The stock has 7 warning signs investors should review. Among 687 Drug Manufacturers companies, Cann Group ranks better than 72.49% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cann Group's Debt-to-EBITDA or its related term are showing as below:
ASX:CAN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.51 Med: -1.42 Max: 0.51
Current: 0.51
During the past 9 years, the highest Debt-to-EBITDA Ratio of Cann Group was 0.51. The lowest was -8.51. And the median was -1.42.
ASX:CAN's Debt-to-EBITDA is ranked better than 72.49% of 687
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs ASX:CAN: 0.51
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cann Group Debt-to-EBITDA Related Terms
Cann Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cann Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cann Group Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cann Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cann Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Cann Group (ASX:CAN) has a Debt-to-EBITDA of 0.22 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cann Group. According to the industry distribution chart, Cann Group ranks #189 out of 687 companies in the Drug Manufacturers industry, placing it in the top 27.5%.
Is Cann Group's Debt-to-EBITDA too high?
Cann Group's current Debt-to-EBITDA is 0.22. The Drug Manufacturers industry median Debt-to-EBITDA is 1.65. Cann Group's value of 0.22 is 86.7% below this industry median. Based on the distribution chart, Cann Group ranks #189 out of 687 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Cann Group's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #189 out of 687 companies for Debt-to-EBITDA. This puts Cann Group in the upper half of its industry. The industry median Debt-to-EBITDA is 1.65. Cann Group's value of 0.22 is 86.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cann Group's current Debt-to-EBITDA of 0.22 is 86.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cann Group. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current Debt-to-EBITDA is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 77.5% below its estimated fair value. The current Debt-to-EBITDA is 0.22 and 86.7% below the Drug Manufacturers industry median of 1.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current Debt-to-EBITDA is 0.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CAN has been successfully added to your 